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A B S T R A C T
Background
The occurrence of factor inhibitory antibodies, or inhibitors, is a significant complication in the care of individuals with congenital
haemophilia A or B. Currently, immune tolerance induction is the only known intervention to successfully eradicate inhibitors.However,
ideal dosing regimens, and the comparative safety and efficacy of different immune tolerance induction regimens have not yet been
established.
Objectives
The objective of this review was to assess the effects of immune tolerance induction (different protocols of this therapy versus each
other, or versus only bypassing agents) for treating inhibitors in people with congenital haemophilia A or B.
Search methods
We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group’s Coagulopathies Trials Register, compiled from electronic
database searches and handsearching of journals and conference abstract books. We also searched: MEDLINE (from 1946 to 15 July
2013); Embase (from1980 to 15 July 2013) via theOVIDplatform;CINAHL (from conception to 15 July 2013); andClinicalTrials.gov
(most recent search: 15 July 2013). We also searched the reference lists of relevant articles and reviews.
Selection criteria
Randomised controlled trials comparing either different immune tolerance induction regimens or immune tolerance induction versus
only bypassing therapy for the eradication of factor inhibitory antibodies in patients with congenital haemophilia A or B.
Data collection and analysis
Two review authors independently completed data collection, extraction and assessment of the risk of bias of trials.
Main results
One methodologically sound randomised controlled trial met the inclusion criteria and was included in the review. One further
randomised controlled trial has been recently stopped, but it has not yet been reported.
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The included multinational trial randomised 115 paediatric participants with severe haemophilia A and high-responding inhibitors,
for whom this was the first attempt at immune tolerance induction, to receive either a low dose (50 IU/kg of factor VIII concentrate
three times per week) or a high dose (200 IU/kg of factor VIII daily). Although, there was no statistically significant difference in the
success of immune tolerance induction between treatment arms, the confidence intervals were too wide to infer no effect: 24 out of
58 participants (46.6%) in the low-dose group and 22 out of 57 (38.6%) in the high-dose group experiencing full tolerance, risk ratio
1.07 (95% CI 0.68 to 1.68) (moderate quality evidence). The rate of infection was not statistically different between groups, but again
confidence intervals were too wide. Of those patients who had a central venous catheter device, 19 out of 47 participants (40.4%) in
the low-dose arm had 69 infections, and 22 out of 52 participants (42.3%) in the high-dose arm had 55 infections, risk ratio 0.96 (95%
CI 0.60 to 1.53) (moderate quality evidence). However, participants in the low-dose immune tolerance induction group experienced
significantly more bleeding episodes (50 out of 58 participants (86.2%) experienced one or more bleeding events) than those in the
high-dose group (36 out of 57 participants (63.1%) experienced one or more bleeding events), risk ratio 1.36 (95% CI 1.09 to 1.71)
(low quality evidence). One factor VIII reaction, one incidence of trauma and 13 incidences of needing to insert or remove the catheter
were reported as trial-related serious adverse events; however, the treatment group where these events occurred was not specified. No
incidence of nephrotic syndrome was reported.
Authors’ conclusions
We did not find any randomised controlled trial-based comparison of immune tolerance induction with alternate treatment schemes
(i.e. bypassing agents for bleeding only). In a single randomised trial, there were no significant differences in the immune tolerance
induction success rate between different dosing regimens, which may have been due to imprecision of the estimate. There is low-
quality evidence to suggest that high-dose immune tolerance induction may induce tolerance more quickly which is associated with
fewer bleeding complications. The choice of immune tolerance induction regimen should be considered individually for each case,
until further research provides additional evidence.
P L A I N L A N G U A G E S U M M A R Y
Immune tolerance induction to destroy inhibitors in people with haemophilia A or B
Review question
We reviewed evidence about the effect of immune tolerance induction to remove inhibitors in people with haemophilia A and B.
Background
Haemophilia A and B are inherited bleeding disorders, where affected people are missing a clotting factor in their blood, which is needed
for normal blood clotting. Without this factor, people with haemophilia cannot make proper clots, and they may bleed for a much
longer time than normal after an injury, or may experience sudden and unexpected bleeding inside the body and into joints. These
bleeding incidents can cause permanent damage to the affected area and can be life threatening. The current treatment for haemophilia
is replacement therapy, where the missing clotting factor is injected into the blood. Sometimes, when the missing clotting factor is
introduced, the person’s immune system will think it is a foreign body, and try to eliminate it with molecules called inhibitors. When
a person with haemophilia develops an inhibitor, the injected clotting factor is destroyed before it can stop the bleeding. This is a very
serious problem that affects almost one in three people with haemophilia A and approximately one in 30 people with haemophilia B.
Immune tolerance induction is a treatment to make the immune system get used to the clotting factor, so that it no longer rejects the
factor. This treatment, which involves giving large doses of factor concentrate, is currently used at different doses. We are unsure of
how the dosing options work and how safe they are. To discover this, we searched the evidence until July 2013.
Trial characteristics
We found one randomised trial that compared high- and low-dose immune tolerance induction, which included 115 males with
haemophilia A and inhibitors.
Key results and conclusions
The single included trial was too small to be certain that both doses of immune tolerance induction were equally successful at removing
inhibitors. However, the high-dose treatment destroyed all inhibitors faster and with less bleeding events than the low-dose treatment.
Since there was only one available trial, further trials are needed to establish the best immune tolerance induction regimen with respect
to starting time, dosing intensity and frequency.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Low-dose ITI compared with high-dose ITI for inhibitor eradication
Patient or population: persons with severe haemophilia A and factor inhibitory antibodies
Settings: one included trial is a multi-national, multi-centre trial
Intervention: low-dose ITI (50 IU/kg of FVIII 3-times per week)
Comparison: high-dose ITI (200 IU/kg of FVIII daily)
Outcomes Relative effect
(95% CI)4
No of Participants
(studies)
Quality of the evidence
(GRADE)1
Comments
Total ITI Success RR 1.07 (0.68 to 1.68) 115 participants
(1study)
⊕⊕⊕©
moderate2
All bleeding events RR 1.36 (1.09 to 1.71) 115 participants
(1study)
⊕⊕©©
low2,3
CVAD infections RR 0.96 (0.60 to 1.53) 99 participants
(1study)
⊕⊕⊕©
moderate2
Of 115 participants, only
99 were reported to have
a CVAD, and CVAD infec-
tions were the only type
of infections reported
Severe allergic reaction Treatment group of sin-
gle allergic event was not
available, hence could not
assess this outcome
Nephrotic symdrome No data available
GRADE Working Group grades of evidence
High quality: further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: we are very uncertain about the estimate.
1Since there was only one included trial, we could not assess inconsistency, and we did not use this criterion to rate down.
2Downgraded for imprecision: one included study did not give us sufficient confidence about the precision of our result, and we cannot
fully exclude a difference among the two regimens.
3Downgraded for risk of bias: given that the outcomes were self-reported, we thought the lack of blinding of participants may have
introduced bias in outcome assessment.
4Information about rate of spontaneous inhibitor tolerance (i.e. a control group) is not available in the literature, hence we cannot calculate
and include risks for the control group. However, in a cohort of 79 high responding inhibitor patients, who did not undergo ITIT, 23 (29%)
cleared the inhibitor over a median of 6 years (Tagariello 2013).
CI: confidence Interval
CVAD: central venous access device
FVIII: factor VIII
GRADE: Grading of Recommendations Assessment, Development and Evaluation
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ITI: immune tolerance induction
B A C K G R O U N D
Description of the condition
Haemophilia A and B are congenital X-linked inherited blood dis-
orders. While haemophilia A (estimated incidence rate of 1 per
5000 live births) is more common than haemophilia B (estimated
incidence rate of 1 per 30,000 live births), both conditions are
caused by the partial or complete absence of coagulation factor
VIII or IX, respectively (Mannucci 2001). Diminished levels of
the coagulation factor disrupts the blood clotting mechanism in
affected individuals to different degrees depending on the level
of factor present: mild haemophilia (clotting factors levels greater
than 5 IU/dL); moderate haemophilia (clotting factor levels be-
tween 1 and 5 IU/dL); and severe haemophilia (clotting factor
levels below 1 IU/dL) (Coppola 2010).
Individuals with haemophilia are at increased risk for adverse out-
comes, such as excessive and uncontrollable bleeding when experi-
encing external trauma or undergoing surgical procedures. These
conditions can negatively affect the quality of life of an affected
individual. Individuals with mild or moderate haemophilia rarely
experience spontaneous bleeding episodes, and often only bleed
after experiencing major trauma or undergoing invasive proce-
dures. Individuals with severe haemophilia are at highest risk for
severe and frequent spontaneous bleeding incidences, and often
experience recurrent or chronic bleeding into joints and muscles,
which can evolve into joint arthropathy.
Individuals receiving factor VIII or IX replacement therapy can
develop antibodies against factor VIII or IX, called inhibitors,
which interfere with factor coagulation activity by neutralising the
effect of exogenous factor concentrate. Inhibitor development is
a major challenge to the care of individuals with haemophilia, as
their development can preclude safe and effective therapy of fac-
tor concentrate infusion. Disease type and severity influences in-
hibitor development. The odds of developing inhibitory antibod-
ies are higher soon after the beginning of treatment and in peo-
ple with severe haemophilia A (estimated incidence: 30%) com-
pared to people with haemophilia B (estimated incidence: 3%)
(Coppola 2010; DiMichele 2007). Individuals with more severe
haemophilia are also more likely to develop inhibitory antibod-
ies.There are two main goals of treatment for individuals who
have haemophilia and develop inhibitors: the first is to efficiently
manage bleeding episodes, which is usually done with bypassing
agents such as recombinant activated factor VII, the second goal is
to eradicate inhibitor presence with interventions such as immune
tolerance induction (ITI) (Iorio 2010).
Description of the intervention
Currently, strategies addressing inhibitor reduction and eradica-
tion are diverse and heterogenous. For individuals with low-re-
sponding inhibitors, administration of increased dosages of factor
VIII or IX can be used to manage the presence of inhibitors dur-
ing bleeding episodes. In the case of high-responding inhibitors,
to date, ITI is the preferential treatment to eradicate inhibitors
in people with haemophilia (Di Michele 2011). While the exact
mechanism through which ITI can induce tolerance remains un-
clear, the general concept is that large doses of factor concentrate
may decrease immune response through decreased production of
factor inhibitory antibodies. Proposed molecular mechanisms in-
clude clonal deletion, anergy and ignorance of specific cellular tar-
gets (Astermark 2011). Treatment with ITI involves the frequent
administration of factor VIII or IX concentrate to patients with
inhibitors, with the long-term goal of eradicating inhibitor pres-
ence. It should be noted, that in people with haemophilia B who
have developed inhibitors, factor IX can only be used for low-re-
sponding inhibitors or ITI, when the individual does not experi-
ence an allergic reaction to factor IX or products containing factor
IX (DiMichele 2007). Central venous access devices (CVADs),
which are commonly used to administer treatment in patients
with haemophilia and inhibitors, are associated with many com-
plications including CVAD-associated infections and thromboses
(Komvilaisak 2006). Aside from allergic reactions, another com-
plication associated with ITI is development of nephrotic syn-
drome, which is particular to individuals with haemophilia B and
inhibitors (DiMichele 2007).
Other interventions to manage inhibitor levels include the use
of bypassing agents (such as recombinant activated factor VIIa
or aPCC), which can be used to manage inhibitors in the event
of bleeding episodes. Also, the use of immunosuppressive drugs,
such as prednisone, oral cyclophosphamide or rituximab (an anti-
CD20 monoclonal antibody), work to suppress immune system
function and have been shown to aid eradication of inhibitors
in people with congenital haemophilia A and B (Carcao 2006).
Further, immunoadsorption strategies to remove immunoglobulin
factor antibodies, via highly specific extracorporeal perfusion of
blood and plasma, have been used to reduce high inhibitor levels
to allow for more effective ITI (Freedman 2003; Freedman 2004).
However, the use of and the regimen given for these interventions
are heterogeneous.
Literature reporting on the administration and regimen used for
ITI is very varied.Much of the current knowledge has been gleaned
from people with haemophilia A, with limited data regarding ITI
use in those with haemophilia B. Prior studies investigating the use
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of ITI have employed numerous regimens with regards to dosage,
timing and type of concentrate, among other variables. Universal
protocols for ITI in people with haemophilia A and B do not yet
exist.
How the intervention might work
The development of inhibitors in people with haemophilia poses
many challenges to care. Patients who develop inhibitory antibod-
ies for factor VIII or IX have been shown to experience increased
adverse outcomes. According to Tagliaferri, having an inhibitor
was associated with higher mortality rates (Tagliaferri 2010). Fur-
thermore, individuals developing inhibitors require a more exten-
sive, and often more complicated, treatment regimen to manage
their disease than individuals of comparable disease severity, who
do not develop inhibitors (Gringeri 2003). Inhibitor development
in the haemophilia population has been related to increased ortho-
pedic complications that results in a lower quality of life (Gringeri
2003; Scalone 2006). From an economic standpoint, inhibitor
development drastically increases the cost of care, thereby increas-
ing the economic burden (Di Minno 2010). The use of ITI, with
its potential to eradicate inhibitory antibodies in individuals with
haemophilia A and B, might be an avenue to re-establish normal-
isation of treatment in individuals who have developed inhibitory
antibodies.
Why it is important to do this review
In patients with haemophilia, the development of inhibitors af-
ter the commencement of therapy instigates many challenges for
both the healthcare provider and the patient. Treatment with ITI
presents one method of countering the effects of inhibitors in this
group. However, existing studies provide no unequivocal results
on the ideal time of ITI initiation, the optimal regimen, and ac-
tual effectiveness. The proposed review aims to summarise the
evidence with regards to ITI in the haemophilia population. We
wish to compare ITI between different factor-based regimens and
to other interventions used with patients with haemophilia who
develop inhibitors, to evaluate its effect on inhibitor eradication.
Results of this review may be used to inform future research, to
aid clinicians in making informed clinical decisions, and perhaps
may be the first step in promoting the creation of universal ITI
protocols.
O B J E C T I V E S
To determine the efficacy and adverse effects of ITI in people with
congenital haemophilia A and B and inhibitors.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) and controlled clinical trials
(CCTs), both published and unpublished, were eligible for inclu-
sion in any publication form (i.e. abstract, letter, article, etc).
Types of participants
Individuals (without any age or sex restrictions) who have been
diagnosed with congenital haemophilia A or B, and who have
factorVIII or IX inhibitors.We excluded individualswith acquired
haemophilia.
Types of interventions
Immune tolerance induction, which is the administration of any
form (plasma-derived or recombinant factor of any preparation
marketed under any brand name) of factor VIII or IX with the
intent of eradicating the inhibitor. We considered trials including
all variations regarding dosage, timing, duration and mode of de-
livery for ITI.
We considered the following comparisons:
1. ITI versus other factor concentrate based regimens (i.e.
different ITI protocols, which may be supplemented with
bypassing agents to control bleeding events);
2. ITI (any regimen) versus use of only bypassing agents.
Types of outcome measures
Primary outcomes
1. Efficacy: inhibitor eradication, defined as
i) unmeasurable inhibitor
ii) normal factor VIII or IX recovery
iii) normal factor VIII or IX half-life
2. Safety: incidence of adverse events (such as musculoskeletal
bleeding events, all bleeding events, administration site
infections, severe allergic reactions (SAE), and nephrotic
syndrome)
Secondary outcomes
1. Joint function (measured using a validated scale, e.g. the
Haemophilia Joint Health Score (HJHS), the Denver Score, or
the Orthopaedic Joint Score (OJS))
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2. Quality of life (measured using a validated scale, e.g. the
haemophilia-specific quality of life questionnaire (Hemo-QoL),
the Canadian Hemophilia Outcomes-Kids Life Assessment Tool
(CHO-KLAT), the 36-item short-form SF-36, or the EuroQoL
Group’s five-dimension questionnaire (EQ-5D)
3. Cost and resource utilisation (any costs relating to the
treatment including, but not limited to, cost of coagulation
factors, and costs associated with hospital visits or
hospitalisations due to bleeding events).
The stated secondary outcome of cost and resource utilisation will
be measured through cost-effectiveness data, through reported in-
cremental cost effectiveness ratios (ICERs) using quality adjusted
life years (QALYs).
Search methods for identification of studies
Electronic searches
We searched the Cochrane Cystic Fibrosis and Genetic Disorders
Group’s Coagulopathies Trials Register for relevant studies using
the terms: (factor VIII* OR factor IX) AND haemophilia*.
The Coagulopathies Register is compiled from electronic searches
of the Cochrane Central Register of Controlled Trials (CEN-
TRAL) (updated for each new issue of The Cochrane Library),
quarterly searches of MEDLINE and prospective hand-search-
ing of one specialised journal, Haemophilia. Unpublished work
is identified by searching the abstract books of five major con-
ferences: the European Haematology Association conference; the
American Society of Hematology conference; the British Society
for Haematology Annual Scientific Meeting; the International So-
ciety of Haemostasis and Thrombosis Congresses; and the In-
ternational Congresses of World Federation of Haemophilia. For
full details of all searching activities for the register, please see
the relevant section of the Cochrane Cystic Fibrosis and Genetic
Disorders Group Module.
In addition, we performed searches in the MEDLINE and Em-
base databases (using the Ovid platform). We also searched the
CINAHL database for relevant reports.We searched each database
from the earliest possible date (for MEDLINE: January 1946, for
Embase: January 1974; and for CINAHL: January 1950) to July
15 2013. The full search strategies are available in the appendices
of the review (Appendix 1; Appendix 2; Appendix 3). There were
no language restrictions placed on these searches.
Searching other resources
We reviewed the bibliographic reference lists of all retrieved studies
for additional eligible trials. We also searched trial registries, such
asClinicalTrials.gov (www.clinicaltrials.gov) and the International
Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/
en/) to identify ongoing trials.
Data collection and analysis
Selection of studies
Twoauthors (AA,MM) independently reviewed the abstracts from
the search results to identify articles that might be relevant to the
review. Two authors retrieved the full texts (unless only published
in abstract form) for those articles considered to be potentially
relevant to the review. The same two authors assessed the full text
manuscripts to select the included trial. The authors discussed
conflicting cases until they reached a consensus.
Data extraction and management
Two authors (AA, MM) independently extracted data using pre-
designed data forms. The same two authors resolved any differ-
ences in data extraction through discussion. The authors extracted
data on the following topics from the included trial:
• inclusion criteria of trial;
• location and time frame of trial;
• participant number and demographics;
• trial methods;
• trial design;
• type, characteristics and duration of the intervention and
control (if applicable) groups;
• outcome measures and description;
• information regarding limitations or bias (or both).
Assessment of risk of bias in included studies
The authors assessed the risk of bias in the included trial using the
Cochrane Collaboration’s tool for assessing risk of bias’ as outlined
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011). For the included trial, we assessed and classified
the following seven criteria as having either a ’high risk’, ’low risk’
or ’unclear risk’ of bias.
1. Sequence generation
2. Allocation concealment
3. Blinding of participants and personnel
4. Blinding of outcome assessment
5. Incomplete outcome data
6. Selective outcome reporting
7. Other issues
Measures of treatment effect
The one included trial reported ITI success as a dichotomous out-
come (i.e. yes or no that the individual had successful tolerance).
We used a risk ratio (RR) and the corresponding 95% confidence
intervals (CI) to measure treatment effect.
In future updates, where there may be heterogeneity in outcome
reporting, we plan to use the following measures of treatment
effect
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• Outcomes represented as a rate: we will use a rate ratio,
with the corresponding CIs.
• Continuous outcomes: we will use a standardized mean
difference (SMD), with the corresponding CIs.
• Time-to-event data: we will use a hazard ratio, with the
corresponding CIs.
• Economic data: we will use point estimates, with the
corresponding measure of variance (such as standard deviation
(SD)). We also plan to report ranges of cost data, if it is the more
appropriate treatment measure. If our search provides multiple
trials that report cost data, we will critically evaluate the data,
taking into account the measurement and reporting methods
and the context of the trial. If data are deemed to be similar
enough and are equivalent across studies, we will pool data using
methodology described in the Cochrane Handbook for Systematic
Reviews (Shemilt 2011). Given that the pooling of economic
data can be very controversial, if we report data in this way, we
will present a critical analysis of the data in the results to ensure
transparency and reproducibility. If we do not pool economic
data, we will include a narrative summary of these data in the
review.
Unit of analysis issues
Given that haemophilia, related treatments and potential for com-
plications can be variable between individuals, we expected that
the unit of analysis for most of the trials to be the individual. For
this review, we did not expect to find any cluster-randomised trials
as feasibility would have been a concern for cluster trials. Further-
more, ITI for inhibitor eradication is not an appropriate treatment
to study in a cross-over trial. In the future, if we encounter trials
with multiple intervention groups, we plan to combine treatment
groups to create a single pair-wise comparison that is most relevant
to our outcome.
Dealing with missing data
Where data were missing from the included trial, we applied an
intention-to-treat analysis, as was also employed by the trial au-
thors. We also noted levels of missing data, and the reasons why
they were missing. We did not attempt to contact trial authors for
missing data.
Assessment of heterogeneity
Since only one trial was eligible for inclusion in this review, we did
not need to assess heterogeneity. In future updates of this review,
if we include more trials, we will assess heterogeneity as outlined
in our original protocol, as follows.
If we include multiple trials in future revisions of this review, we
will initially identify statistical heterogeneity by using the Chi2
test, with the null hypothesis being that there is no significant
heterogeneity across trial results. We will conclude that the results
of the trials are not heterogeneous if we cannot reject the null
hypothesis (i.e. if there is no statistically significant difference be-
tween the different trials). As suggested by theCochrane Handbook
for Systematic Reviews of Interventions, to have a more conservative
test we will use a significance level of P = 0.1 rather than P = 0.05.
This will help us have further confidence that a non-significant
result indicates a lack of homogeneity.
We will conduct a meta-analysis if there are multiple trials with
consistent treatment effects. We will use the I2 method to provide
evidence for heterogeneity in our meta-analysis. Our interpreta-
tion thresholds, as suggested in theCochrane Handbook for System-
atic Reviews of Interventions, will be as follows (Deeks 2011):
• 0% to 40%: might not be important;
• 30% to 60%: may represent moderate heterogeneity;
• 50% to 90%: may represent substantial heterogeneity;
• 75% to 100%: considerable heterogeneity.
Final interpretation will depend on number and characteristics of
the retrieved studies.
Assessment of reporting biases
Since only one trial was included, it was not appropriate to con-
struct a funnel plot to assess reporting bias. Instead, we compared
the data reported in the trial report to the trial protocol to detect
any differences that may be attributable to reporting bias.
For future updates of the review, if more trials are included in the
review, to detect reporting bias, we plan to construct a funnel plot
and assess it for symmetry. If any asymmetry is detected, then we
plan to investigate the cause to see if it is attributable to reporting
bias. If there are greater than 10 trials included in the funnel plot,
then we will use the test proposed by Egger to test for asymmetry
(Egger 1997). Further, in an attempt to identify selective reporting,
we will compare information as reported in trial protocols with the
actual methods and outcomes reported in the published papers in
an attempt to identify any differences.
Data synthesis
We had originally planned to statistically combine data in a meta-
analysis to acquire one estimate of treatment effect.However, with
only one eligible trial, data synthesis was not possible. If more
than one trial is included in future updates of this review, and it is
appropriate to combine trials, we will synthesize data as outlined
in our original protocol, as follows.
We plan to undertake a fixed-effectmodel analysis and to switch to
random-effectsmodel use if we identify substantial or considerable
heterogeneity in our meta-analysis. We will evaluate heterogeneity
as described above.
Subgroup analysis and investigation of heterogeneity
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In order to investigate any heterogeneity in future updates, if we
include a sufficient number of trials (n = 10), we plan to under-
take the following four subgroup analyses for each of our primary
outcomes:
1. patients for whom this is the first ITI attempt versus if ITI
has been previously attempted;
2. ITI in individuals who developed an inhibitor as previously-
untreated patients versus those as previously-treated patients;
3. ITI in adults versus children;
4. ITI in patients with high titer inhibitors (more than 5
Bethesda units (BU)) versus low titer inhibitors (less than 5 BU).
However, these groups were not addressed in the one eligible trial.
Sensitivity analysis
For future updates of this review, if there are a sufficient number
of comparable trials (10 or more), we will perform sensitivity anal-
yses to exclude trials with clearly inadequate allocation of conceal-
ment, randomisation, or blinding (high risk of bias). If possible,
we will also explore the impact of including trials with high levels
of missing data in the overall assessment of treatment effect. A
high level of missing data is defined as any level of missing data
that is sufficient to reverse the treatment effect.
Summary of findings table
Please refer to the summary of findings table (Summary of findings
for the main comparison).
We included all assessable outcomes, from the one included trial
in the summary of findings table. We used the GRADE approach
to assess the quality of evidence. However, since there was only
one included trial we were unable to assess inconsistency for all
included outcomes. We hope that with the addition of more trials
we will be able to assess this GRADE category in future updates.
R E S U L T S
Description of studies
Results of the search
For the detailed trial selection flow chart, please refer to the figures
section (Figure 1).
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Figure 1. Study flow diagram.
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The searches identified 1792 potential articles (after duplicates
were removed). Two review authors independently conducted ini-
tial screening at the title level. At this point, 1738 records were ex-
cluded as they did not meet the inclusion criteria. One article was
classified as ongoing (NCT01051544). The full text of each of the
remaining 53 articles was retrieved and assessed for eligibility and
of these, one trial (six references) was included in the review (Hay
2012) and 47 articles reporting 44 unique trials were excluded.
Included studies
One trial was eligible for inclusion, the ’International Immune
Tolerance Induction (I-ITI) Trial’, which included 115 patients
(Hay 2012).
The Hay trial was a multicentre, prospective RCT, which was
conducted in 70 centres spanning 17 countries. The trial aimed to
compare the efficacy and safety of high-dose versus low-dose ITI,
under the hypothesis that ITI outcome is independent of dosing
regimen. The trial was stopped early because of futility and safety
concerns, as there were significantly more bleeding events in the
low-dose arm compared to the high-dose arm.
In all, 134 male patients less than seven years of age, with severe
haemophilia A, who had a high-responding inhibitory antibody
to factor VIII were enrolled in the trial. All patients were identified
as ’good-risk’ meaning an expected favourable response to ITI,
as predicted by their peak historical inhibitor titre was between
5 and 200 BU/mL, and the starting inhibitor titre was 10 BU/
mL or less prior to randomisation or decreased to this level in
less than 12 months. Of enrolled participants, 10 were removed
from the trial prior to randomisation,and eight participants were
awaiting randomisation at the time of trial termination. A further
participant was withdrawn from the trial after randomisation but
before starting ITI, and hence was excluded from the analysis.
Of the remaining 115 participants included in the analysis, 58
participants were randomised to receive low-dose ITI (50 IU/kg
of factor VIII three times per week), and 57 participants were
randomised to receive high-dose ITI (200 IU/kg of factor VIII
daily). The primary endpoint was ITI outcome (either successful
tolerance, partial response, trial failure, or relapse) (Hay 2012).
Excluded studies
A total of 47 articles reporting 44 unique studies were excluded, of
these, 35 articles reported on non-randomised studies and 12 were
reported as having a randomised trial design but were excluded
because they had the incorrect intervention or incorrect outcomes,
or both.
Ongoing studies
One study, the RESIST NAIVE, was characterised as ’ongoing’
(NCT01051544).
The RESIST NAIVE study is a prospective, RCT, which has been
recently stopped for difficulty in recruiting participants. It planned
to investigate the safety and efficacy of ITI on patients with severe
haemophilia A who have not previously undergone ITI, but have
a risk factor for ITI failure, such as having a peak inhibitor titer
more than 200 BU, having an inhibitor titer more than 10 BU
at ITI start, being older than seven years of age or having the
time between inhibitor occurrence and ITI more than two years
(NCT01051544).
Risk of bias in included studies
Please refer to the figures section of the review (Figure 2; Figure
3).
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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We assessed the risk of bias for the included trial was according to
the pre-defined criteria given in the methods section (Methods).
Overall, we considered the included trial to be at a low risk for
bias.
Allocation
The included trial was judged to have a low risk of bias for random
sequence generation as it was reported that patients were computer
randomised using minimization for product type (either plasma
derived or recombinant) and starting inhibitor titre (either above
or below 5 BU/mL). However, as the trial reports did not indicate
the method of allocation concealment, this category was judged
as having an unclear risk of bias.
Blinding
There was no reporting of blinding, at any level. Given the inter-
vention it was not not feasible to blind participants to their treat-
ment allocation. However, it perhaps would have been possible
to blind outcome assessors. This lack of blinding was judged to
have variable effects on the bias introduced for the various out-
comes. For the primary outcome of tolerance induction, which
is an objective and laboratory-confirmed endpoint, we did not
think that the lack of blinding would have much effect on the
interpretation of results, and hence judged this category to be at
low risk of bias. However, for secondary outcomes that were self-
reported (i.e. frequency of bleeding events), the lack of blinding
may have impacted outcome assessment. Hence, we judged this
category to be at high risk of bias for the secondary outcomes. In
light of this, results for secondary outcomes should be interpreted
with caution.
Incomplete outcome data
While there were some dropouts and withdrawals reported in the
included trial, they were balanced across treatment arms and rea-
sons for leaving the trial were well-documented. Further, analysis
was conducted on an intention-to-treat basis. For these reasons we
judged this category to be at low risk of bias.
Selective reporting
We judged this category to be at low risk of bias because the
reported outcomes match those listed in the protocol, and are
comprehensively reported.
Other potential sources of bias
We did not identify any other potential sources of bias.
Effects of interventions
See: Summary of findings for the main comparison
Nometa-analysis could be completed as there was only one eligible
trial. As more trials are available for inclusion, future updates of
this review may include statistical pooling of data.
Given the participants included in this trial, three out of our
four pre-specified subgroups (first ITI attempt versus previous ITI
event, ITI for PTPs versus ITI for PUPs, and ITI for adults ver-
sus children) were not addressed in this trial. Data for our fourth
subgroup (ITI in patients with high titer inhibitors (more than
five BU) versus low titer inhibitors (less than five BU)) were not
reported.
Data from the one eligible and included trial (n = 115) are reported
below (Hay 2012).
Primary Outcomes
1. Efficacy: total ITI success
For the one included trial, the primary outcome was ITI toler-
ance, which was analogous to our primary outcome of inhibitor
eradication (Hay 2012). Participants who reached successful ITI
tolerance all had a negative inhibitor titer, factor VIII recovery
was more than 66% of expected, and factor VIII recovery more
than six hours. There was no significant difference in participants
achieving tolerance between the two treatment groups; overall 24
participants on low-dose ITI and 22 participants on high-dose
ITI achieved successful tolerance, RR 1.07 (95% CI 0.68 to 1.68)
(115 participants) (Analysis 1.1).
2. Safety
a. Musculoskeletal bleeding
Separate data for different types of bleeding events were not re-
ported in the included trial, hence we could not statistically pool
the data. However, in their report, the trial authors stated that
there was no statistically significant difference between treatment
arms in terms of musculoskeletal bleeding incidents.
b. All bleeding events
In the included trial, there were significantly more bleeding events
in the low-dose arm than in the high-dose arm over the course of
ITI treatment, RR 1.36 (95% CI 1.09 to 1.71) (115 participants)
(Analysis 1.2).
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c. Infection
The eligible trial reported the number of CVAD infections (Hay
2012). Of the 58 low-dose participants, 47 had a CVAD, and of
the 57 high-dose participants, 52 had a CVAD. Of patients who
had a CVAD, 19 in the low-dose arm had 69 infections, and 22
participants in the high-dose arm had 55 infections. There were
no significant differences in incidence of CVAD infections, RR
0.96 (95% CI 0.60, 1.53) (99 participants) (Analysis 1.2). Ten
non-catheter-related infections were reported, however, they were
deemed to be not trial related, and their distribution over trial
arms was not reported.
d. Severe allergic reactions (SAE)
One factor VIII reaction was reported as a trial-related SAE.How-
ever, the treatment group where this reaction occurred was not
reported.
e. Nephrotic syndrome
No incidence of nephrotic syndrome was reported.
f. Other adverse events
Other trial-related serious adverse events included trauma (n =
1) or need to insert or remove catheter (n = 13). However, the
distribution over trial arms was not reported. We did not contact
the trial authors to establish which arm contributed to the adverse
events.
Secondary outcomes
1. Joint function
This outcome was not assessed in the included trial (Hay 2012).
2. Quality of life
This outcome was not assessed in the included trial (Hay 2012).
3. Cost and resource utilisation
Cost-effectiveness was a reported outcome in the trial, however,
data were not available at the time of this review.
D I S C U S S I O N
Summary of main results
There was no statistically significant difference in successful toler-
ance to factor VIII in people with severe haemophilia A and a fac-
tor inhibitory antibody, who received high-dose compared to low-
dose ITI with factor VIII concentrates. However, those receiving
low-dose ITI experienced significantly more bleeding events than
those receiving high-dose ITI.
Overall completeness and applicability of
evidence
This review consists of one RCT comparing two ITI dosing regi-
mens (Hay 2012). However, the results and conclusions that can
be drawn from the review have limited external validity, as they
are only applicable to good-risk, paediatric participants with se-
vere haemophilia A, who had not previously tried ITI for inhibitor
eradication. We were unable to address any of our secondary out-
comes, as there were no data available for these analyses. Further,
because of the specific participant types, we were unable to under-
take our pre-planned subgroup analyses for our primary efficacy
and safety outcomes. Future RCTs investigating the safety and ef-
ficacy of ITI in different patient populations (i.e. participants with
different severity of haemophilia, of different ages, with different
dosing regimens, etc) will help to improve the external validity of
this review in future updates. Unfortunately, it is not likely that
other trials will be undertaken in the near future, and the RESIST
NAIVE trial, designed to fill some of this gap in information, has
been recently discontinued (NCT01051544).
The included trial is the first and only prospective, RCT con-
ducted to compare ITI efficacy and safety in patients with severe
haemophilia A and inhibitors, and provided valuable evidence to
inform ITI treatment (Hay 2012). Despite being stopped early,
this trial shows that RCTs can feasibly be conducted in rare disease
populations. The trial was a multicentre, international trial, which
perhaps suggests that ITI practice is, or can be, standardised inter-
nationally. In addition to the advantages of the prospective, ran-
domised design, the strengths of the included trial include the use
of pre-defined study endpoints and international data collection.
Further, this trial provided valuable prospective evidence about the
pharmacokinetics of factor VIII during ITI and the year following
successful tolerance; it also identified peak inhibitor titer in ITI as
a significant predictor of ITI outcome in the multivariate-regres-
sion analysis.
The results of the Hay trial suggest that both high-dose and low-
dose ITI canbe used in inducing immune tolerance in haemophilia
A patients with factor inhibitory antibodies. Despite the trial be-
ing stopped early, the results suggest that there is no significant
difference between ITI success rate in both groups. Given this,
future cost-effectiveness and quality of life analyses may influence
the choice of dosing regimen in different populations. Accord-
ingly, recent guidelines indicate that the use of ITI and choice
of dosing regimen should be considered on a case-by-case basis
(Benson 2012).The 50 IU/kg every other day can be seen as low-
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dose ITI or high-dose prophylaxis. For patients and clinicians in
low-income settings, it is valuable to know that continuing on a
prophylaxis-like regimen will achieve the same rate of inhibitor
clearance as the high-dose regimen. it remains for future research
to understand the value of continuing inhibitor patients on low-
dose prophylaxis regimens such as those used in China, Egypt,
Algeria and Thailand (median dose being 10 to 15 IU/kg two to
three times per week).
Since the population of the included trial was limited to patients
with severe haemophilia A, the results have limited generalizabil-
ity to patients with haemophilia B. To date, the treatment of
haemophilia B complicated with an inhibitor is guided by anec-
dotal case reports, case studies or observational studies, as there are
no existing guidelines or more methodologically rigorous study
in this area. Given the low prevalence of haemophilia B and the
even lower incidence of inhibitor development, conducting ade-
quately-powered trials to prospectively evaluate the efficacy and
safety of ITI in patients with haemophilia B and inhibitors would
be challenging. However, in comparison to treatment of inhibitors
in people with haemophilia A, treatment of inhibitors in patients
with haemophilia B has a history of increased morbidity due to
severe allergic reactions following administration of factor IX and
development of nephrotic syndrome (Batorova 2013). Given this,
treatment of inhibitors in patients with haemophilia B (i.e. by
using ITI) while perhaps more challenging, is definitely separate
from the treatment of inhibitors in haemophilia A and thus war-
rants separate evidence-based guidance. However, due to the ex-
treme rarity of the condition, it is unlikely that strong evidence
will be available for this area in the foreseeable future.
Upon recommendation by an independent data and safety mon-
itoring board, the included trial was terminated early for safety
concerns, as there were significantly more bleeding events in the
low-dose group than in the high-dose group, and futility concerns,
mainly due to slow recruitment and unlikelihood of reaching the
necessary sample size. At the time the trial was terminated, only
135 patients had been recruited and throughout the course of the
trial 966 bleeding events had been reported (684 in the low-dose
group and 282 in the high-dose group). The original power calcu-
lation indicated that 75 patients would be needed per arm to have
an adequately-powered trial, which would allow for two interim
analyses to be conducted after recruitment of 50 and 100 partici-
pants. No formal stopping rules were indicated. As a consequence,
the trial was underpowered and was limited in its ability to as-
sess the primary outcome. To date, investigators have not reported
long-term treatment effects and long-term adverse events.
Quality of the evidence
The current body of randomised evidence to inform the use of
ITI for inhibitor eradication in haemophilia patients is comprised
of one trial that includes 115 patients. By outcome, the body of
evidence is moderate for the primary outcome of the review (ITI
success), and low for assessable secondary outcomes (bleeding fre-
quency and infection). Please refer to summary of findings table
for the rationale of the evidence assessment (Summary of findings
for themain comparison). The included trial is novel in the field of
haemophilia and has many methodological strengths. Since there
is only one eligible RCT, the results of this review are directly ap-
plicable only to a limited group. We believe that further research
is likely to have an impact on the effect estimates presented in
this review. Currently ITI is the most widely adopted method to
eradicate inhibitory antibodies. Hence, given the limited amount
of randomised evidence, clinicians and policy makers might also
consider high-quality, non-randomised evidence whenmaking de-
cisions.
Potential biases in the review process
Toour knowledge, our review process is free frombias.We took the
following steps to limit bias: our search strategy was reviewed mul-
tiple times to ensure that all relevant trials would be captured; we
searched different sources of data (including different databases,
and clinical trial registries); we pre-specified all outcomes and sub-
groups; we completed all screening in duplicate with a third-party
arbitrator; and we extracted data in duplicate. Future updates of
this review will use similar safeguards to limit bias in the review
process.
Agreements and disagreements with other
studies or reviews
With the exception of the international ITI trial by Hay (Hay
2012), the evidence to inform current clinical practice decisions
for ITI treatment come from registry data and observational stud-
ies, which are largely retrospective cohort studies or case series (Di
Michele 2011; Franchini 2011). Success with ITI and factors that
affect ITI outcome have been retrospectively and prospectively ob-
served in registries, such as the International Immune Tolerance
Registry (IITR) (Mariani 1999), the North American Immune
Tolerance Registry (NAITR) (DiMichele 2009), the German Im-
mune Tolerance Registry (GITR) (Lenk 2000) and the Spanish
Registry (Haya 2001). A further registry, the Prognostic Factors
in Immune Tolerance (PROFIT), is currently still collecting data
(Coppola 2009). Each of these registries has collected data about
ITI dosing regimens and successes. Authors of the included trial
indicated that the lower overall ITI success rate in their trial in
comparison to reporter registry rates is likely attributed to the use
of a standardised definition if ITI success, which has not been
universally used, and the use of an intention-to-treat analysis that
included all patients - both compliant and non-compliant (Hay
2012).
There is some congruence between registry data and the current
trial regarding factors that predict ITI outcome. The NAITR,
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IITR, the Spanish Registry and PROFIT all identified pre-ITI
titer level to be a significant predictor of ITI outcome (Coppola
2009; DiMichele 2009; Haya 2001; Mariani 1999) The NAITR,
GITR, IITR and the Spanish Registry all identified historical peak
titer level to be a predictor of ITI outcome (DiMichele 2009; Haya
2001; Lenk 2000; Mariani 1999). The NAITR and PROFIT reg-
istry found that peak inhibitor titre while on ITI was a signifi-
cant predictor of ITI success (Coppola 2009; DiMichele 2009). In
comparison, the results of theHay trial showed that peak historical
titer and peak inhibitor titer, while on ITI, were significant predic-
tors of ITI outcome in the univariate analysis and peak inhibitor
titer on ITI was the only significant predictor of ITI outcome in
a multivariate regression (Hay 2012).
With respect to dosing options, a previously completedmeta-anal-
ysis of the IITR and NAITR registries showed that the ITI success
rate was similar in good-risk patients receiving either high- or low-
dose ITI (Kroner 1999). This finding is in concordance with the
results of the included trial (Hay 2012). However, since the trial
was stopped early, it did not have sufficient statistical power to
establish therapeutic efficacy. In addition to ITI regimens using
only factor concentrates for inhibitor eradication, some ITI pro-
tocols use immune modulation methods to help improve ITI suc-
cess. Such strategies have had similar success rates to ITI protocols
without immune modulation (Berntorp 2000). Futher research
will need to be conducted to establish the efficacy of ITI proto-
cols with immune modulation, in comparison to those without
immune modulation.
In addition to the ITI registries, two additional non-randomised
studies are ongoing that aim to assess the efficacy and safety of ITI
for inhibitor eradication in people with haemophilia (Kreuz 2014;
NCT01051076). The RESIST EXP trial is a prospective obser-
vational study, which is currently ongoing and recruiting partici-
pants; their target date to complete enrolment is June 2020. RE-
SIST EXP is investigating the efficacy of ITI in participants who
have previously failed ITI with vonWillebrand factor (VWF)-free
factor VIII concentrates (NCT01051076).TheObservational Im-
mune Tolerance Induction (ObsITI) Research Program is an on-
going international, open-label, uncontrolled, non-interventional,
multicentre observational research program that aims todocument
ITI success in patients treated with the Bonn ITI protocol. As a
secondary aim, the program is investigating different factors that
may influence ITI outcome. As of February 2013, 256 patients
from 27 countries have been enrolled (Kreuz 2014).
Two prior reviews were published to assess ITI in people with
haemophilia. A systematic review by Wight considered the use of
ITI in patients with haemophilia A and inhibitors (Wight 2003).
However, this review was conducted prior to the publication of the
Hay trial and conclusions were based on observational evidence.
Due to the heterogeneity of the results, statistical pooling of data
was not possible (Wight 2003). Amore recent review by Franchini
reviewed the use of ITI in patients with severe haemophilia A,
but was also completed prior to the publication of the results of
the International Immune Tolerance Induction Study (Franchini
2011). While neither previous review included the Hay trial, both
narratively reviewed available observational data but were unable
to statistically combine these data.
The choice of ITI regimen (i.e. high- or low-dose) may also be
influenced by cost since there is an eight times higher factor con-
sumption in the high-dose arm compared to the low-dose arm.
The increased cost of treatment of high-dose ITI, however, might
be balanced by the cost of treatment for bleeds in patients with
inhibitors. A recent cost minimisation analysis suggests that ad-
justing factor dose according to bleeding risk status might lower
the cost associated with ITI (Odeyemi 2009). However, further
analyses are necessary to determine themost cost-effective ITI reg-
imen.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Even in the absence of RCT-based evidence of tolerogenic effect,
ITI is the most widely adopted method to eradicate factor in-
hibitory antibodies. Compared to low-dose ITI, high-dose ITI
may be associated with fewer bleeding complications, but without
significant difference in the proportion of those eventually achiev-
ing tolerance. However, this lack of statistical significance may be
due to imprecision as the single included trial was underpowered.
Until further evidence is available, the use of ITI and the regimen
to adopt should be considered individually on a case-by-case basis.
Implications for research
Further research is needed in areas such as the use of immune
modulating agents as adjunct to ITI, use of ITI in different patient
populations, and of different ITI dosing regimens.
Prospective data relating to quality of life, joint health and cost-
effectiveness of ITI will help improve knowledge about different
treatment dimensions of haemophilia patients with inhibitors. In
addition, the use of standardised outcome definitions, as used in
the included trial, will help the future statistical pooling of data.
Haemophilia is a rare disease, within which incidence of inhibitors
is even more rare. This can make it quite difficult to design and
conduct a controlled trial with adequate power to establish statisti-
cal superiority, equivalence or non-inferiority. While the Hay trial
is proof that a randomised trial design can be conducted in a rare
disease population such as haemophilia patients with inhibitors,
there are some scenarios (i.e. ITI in patients with haemophilia B)
where a randomised design would be unsuitable, inefficient, or
unfeasible (Hay 2012).
The termination of the I-ITI study for futility illustrates the diffi-
culties in conducting RCTs to assess differences in inhibitor erad-
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ication strategies. However, the results of this systematic review
point to the possible role of different regimens in minimizing
bleeding episodes. This leaves the field open to future comparative
studies. Sequential or adaptive designs, risk or allocation designs
or bayesian-decision analysis trials might help fill the information
gaps.
As to the absence of RCT-based evidence of the tolerogenic effect
of ITI, while it is highly unlikely and possibly unethical to ran-
domise patients to be treated or not in the wealthy world, every
effort should be made, in the less wealthy countries to obtain as
much information as possible on the natural history of inhibitors
in patients undergoing alternative treatments adopted when ITI
is not feasible (Caram 2011; Tagariello 2013).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Hay 2012
Methods Parallel RCT: computer randomisation using minimisation for product type and starting
inhibitor titre level
Participants 115 participants with severe haemophilia A, and a FVIII inhibitory antibody under-
went randomisation (58 on LD ITI and 57 on HD ITI). Median age at randomisation
(months): 15.6 (LD) versus 14.4 (HD); median inhibitor titre at randomisation (BU/
mL): 5.9 (LD) vs 5.1 (HD); median total time on ITI (months) 16.4 (LD) vs 14.2 (HD)
Interventions Participants were randomised to either LD ITI of 50 IU/kg of FVIII 3-times weekly or
HD ITI of 200 IU/kg of FVIII daily. Product choice and use of central venous access
devices was left to discretion of the clinician at each participating centre. Switching FVIII
brand or source was not permitted
Outcomes Outcomes reported were: 1) ITI success rates; 2) bleeding events; 3) CVAD infections;
4) allergic reactions
Notes After tolerance was achieved, participants were given prophylaxis treatment with 30 IU/
kg of FVIII 3-times a week
Central confirmation of ’critical inhibitor measurements’.
Pre-defined, universal outcome measures.
Trial was stopped early for futility and safety concerns.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Reported that patients were computer ran-
domised using minimization for product
type (either plasma-derived or recombi-
nant) and starting inhibitor titre (either
above or below 5 BU/mL). However, the
allocation ratio was not stated
Allocation concealment (selection bias) Unclear risk Method of allocation concealment was not
reported.
Blinding of participants and personnel
(performance bias)
Tolerance induction
Low risk While not reported, given the nature of the
intervention, it was not possible to blind
participants to the treatment allocation.
However, the primary endpoints of the trial
were objective, laboratory confirmed end-
points. Hence, the lack of blinding may
have less of an impact on such objective
outcomes, in comparison to more subjec-
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Hay 2012 (Continued)
tive outcomes
Blinding of participants and personnel
(performance bias)
Bleeding events
High risk While not reported, given the nature of the
intervention, it was not possible to blind
participants to the treatment allocation.
For patient-reported outcomes like bleed-
ing, the lack of blindingmay have impacted
outcome reporting
Blinding of outcome assessment (detection
bias)
Tolerance induction
Low risk Blinding status of outcome assessors was
not reported. However, we do not antici-
pate that lack of blinding would havemuch
impact in the objectivelymeasured primary
outcome. Further, investigators remained
blinded for the interim analyses by the
DSMB
Blinding of outcome assessment (detection
bias)
Bleeding events
High risk Blinding status of outcome assessors was
not reported. For patient-reported out-
comes such as bleeding, the lack of blinding
may have impacted outcome assessment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Originally 116 participants were ran-
domised, but 1 was withdrawn by inves-
tigator prior to starting ITI, and was not
included in the analysis. Of the 115 ran-
domised participants included in the anal-
ysis, 21 were withdrawn before reaching a
defined trial endpoint (8 were withdrawn
by physicians or parents, 12 were with-
drawn for poor compliance of major proto-
col violations, and 1 participant was lost to
follow up after reaching tolerance). How-
ever, withdrawals were reported to be bal-
anced across treatment arms (12 HD vs 9
LD). Further, analysis was conducted on an
intention-to-treat basis
Selective reporting (reporting bias) Low risk There is no evidence to suggest that there
is selective reporting present in the trial
report, and the data presented seem very
comprehensive. All outcomes listed in the
protocol (found on clinicaltrials.gov; iden-
tifier: NCT00212472) were addressed in
the study report. All outcomes, except cost-
effectiveness comparison between treat-
ment arms, are reported in the primary re-
port. This report states that the “compar-
ative pharmaco-economic analysis of the 2
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Hay 2012 (Continued)
treatment arms is ongoing and will be re-
ported separately.” At the time of this re-
view, information about cost-effectiveness
was not yet available
Other bias Low risk No other sources of bias are expected.
BU: Bethesda units
DSAB: Data Safety and Monitoring Board
FVIII: factor VIII
HD: high dose
ITI: immune tolerance induction
LD: low dose
mL: millilitre
RCT: randomised controlled trial
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Astermark 2007 No ITI comparison arm, and outcome was different.
Baker 2010 Non-randomised: case series.
Batlle 1999 Non-randomised: case series.
Berger 2009 Non-randomised: case series.
Berntorp 2005 No ITI comparison arm.
Carneiro 2002 Non-randomised: case series.
Ewenstein 2000 Incorrect intervention.
Ewing 1988 Non-randomised: case series.
Gouw 2013 Incorrect intervention: regular dosing of FVIII with outcome of inhibitor development
Gruppo 1992 Non-randomised: case series.
Kasuda 2004 Non-randomised: case series.
Klukowska 2005 Non-randomised: case series.
Klukowska 2010 Non-randomised: case series.
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(Continued)
Klukowska 2012 Non-randomised: case series.
Klukowska 2013 Non-randomised: retrospective analysis.
Konkle 2007 Incorrect intervention (rFVIIa) and no ITI arm.
Kucharski 1996 Non-randomised: case series.
Kurth 2008 Non-randomised: retrospective analysis.
Lusher 1980 Incorrect intervention (aPCC).
Lusher 1983 Incorrect intervention (aPCC versus non-activated PCC).
Lusher 1998 Incorrect intervention: trial considered FVIIa for haemorrhage
Manco-Johnson 2002 Non-randomised study: case series.
Mariani 2001 Non-randomised study: editorial article.
Meeks 2013 Non-randomised study: retrospective analysis.
Nilsson 1988 Non-randomised study: case series.
Nilsson 1990 Non-randomised study: case series.
Orsini 2005 Non-randomised study: retrospective analysis.
Palomo 2010 Non-randomised study: case report.
Platokouki 2009 Non-randomised study: case series.
Prentice 1984 Incorrect outcome: bleeding events.
Puetz 2011 Non-randomised study: case series.
Rocino 1999 Non-randomised study: case series.
Rocino 2004 Non-randomised study: case series.
Rothschild 1998 Non-randomised study: case series.
Santagostino 2012 Non-randomised study: retrospective analysis.
Scaraggi 2004 Non-randomised study: case series.
Seremetis 1994 Incorrect intervention: FVIIa for bleeding events..
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(Continued)
Shapiro 1998 Incorrect intervention: FVIIa for bleeding during surgery.
Stiefel 2010 Non-randomised study: case report.
Svirin 2008 Non-randomised study: case series.
Unavar 2000 Non-randomised study: case series.
Valentino 2008 Non-randomised study: case series.
Van Velzen 2012 Non-randomised study: retrospective analysis.
Zozulya 2008 Non-randomised study: prospective observational study.
aPCC: activated prothrombin complex concentrates
FVIIa: factor VIIa
FVIII: factor VIII
ITI: immune tolerance induction
PCC: prothrombin complex concentrates
rFVIIa: recombinant activated factor VIIa
Characteristics of ongoing studies [ordered by study ID]
NCT01051544
Trial name or title Trial of first time ITI in severe haemophilia A patients with inhibitor at high risk of failure: comparison with
FVIII concentrates with or without VWF - RES.I.S.T. Naive (RESIST NAIVE)
Methods Listed as a randomised, open-label, parallel group trial.
Participants Estimated enrolment of 148 male participants of any age who have severe haemophilia A and high-responding
inhibitors. Eligible participants must also have at least 1 of the following risk factors for ITI failure: (1) peak
inhibitor titer > 200 BU; (2) titer at ITI start > 10 BU; (3) age > 7 years; or (4) time between inhibitor
occurrence and ITI > 2 years
Interventions FVIII concentrates with and without von Willebrand concentrates
Outcomes Primary: successful ITI, which is defined as: “the abolition of the inhibitor to < 0.6 BU within 33 months of
ITI with a factor VIII recovery ≥ 66% and half-life≥ 6 hrs, and measured after a 72-hour washout period.”
Secondary: (1) absence of relapse; (2) time to achieve success; (3) compliance to treatment; and (4) cost of
care
Starting date June 2009.
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NCT01051544 (Continued)
Contact information Principal investigator: Nadia P Ewing, City of Hope National Medical Center, Department of Pediatrics,
1500 E. Duarte Rd. Duarte, CA 91010
Notes
BU: Bethesda units
FVIII: factor VIII
HD: high dose
ITI: immune tolerance induction
LD: low dose
VWF: von Willebrand factor
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D A T A A N D A N A L Y S E S
Comparison 1. Low-dose ITI versus high-dose ITI
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Efficacy 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Total ITI success 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Safety 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2.1 All bleeding events 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 CVAD infections 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Analysis 1.1. Comparison 1 Low-dose ITI versus high-dose ITI, Outcome 1 Efficacy.
Review: Immune tolerance induction for treating inhibitors in people with congenital haemophilia A or B
Comparison: 1 Low-dose ITI versus high-dose ITI
Outcome: 1 Efficacy
Study or subgroup Low-dose ITI High-dose ITI Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Total ITI success
Hay 2012 24/58 22/57 1.07 [ 0.68, 1.68 ]
0.05 0.2 1 5 20
Favours low-dose ITI Favours high-dose ITI
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Analysis 1.2. Comparison 1 Low-dose ITI versus high-dose ITI, Outcome 2 Safety.
Review: Immune tolerance induction for treating inhibitors in people with congenital haemophilia A or B
Comparison: 1 Low-dose ITI versus high-dose ITI
Outcome: 2 Safety
Study or subgroup Low-dose ITI High-dose ITI Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 All bleeding events
Hay 2012 50/58 36/57 1.36 [ 1.09, 1.71 ]
2 CVAD infections
Hay 2012 19/47 22/52 0.96 [ 0.60, 1.53 ]
0.01 0.1 1 10 100
Favours low-dose ITI Favours high-dose ITI
A P P E N D I C E S
Appendix 1. Search strategy for MEDLINE and Embase via OVID platform (last search July 15 2013)
Search terms
1 Hemophilia A/
2 Hemophilia B/
3 Hemophilia A.mp.
4 Hemophilia B.mp.
5 Haemophilia A.mp.
6 Haemophilia B.mp.
7 Hemophil:.mp.
8 Haemophil:.mp.
9 Factor VIII/
10 Factor VIII.mp.
11 Factor 8.mp.
12 Factor XI/
13 Factor XI.mp.
14 Factor 9.mp.
15 Clotting factor.mp.
16 Recombinate.mp.
17 Kogenate.mp.
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(Continued)
18 Helixate.mp.
19 Advate.mp.
20 Xyntha.mp.
21 Refacto.mp.
22 Benefix.mp.
23 Humate P.mp.
24 Fandhi.mp.
25 Alphanate.mp.
26 Alphanine.mp.
27 Wilate.mp.
28 Immunate.mp.
29 Immunine.mp.
30 Hemophil.mp.
31 Nonacog.mp.
32 Koate.mp.
33 Cryobulin.mp.
34 haemophilus influenzae/
35 haemophilus influenzae.mp.
36 hemophilus influenzae.mp.
37 34 or 35 or 36
38 1 or 2
39 3 or 4 or 5 or 6
40 7 or 8
41 40 not 37
42 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30
or 31 or 32 or 33
43 39 or 41 or 42
44 inhibi:.mp.
45 43 and 44
46 38 and 45
47 Immune Tolerance/
48 immune tolerance.mp.
49 immune tolerance induction.mp.
50 ITI.mp. (1076)
51 immunotolerance.mp.
52 Bonn protocol.mp.
53 malmo protocol.mp.
54 47 or 48 or 49 or 50 or 51 or 52 or 53
55 46 and 54
56 limit 55 to humans
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Appendix 2. Search strategy for CINAHL (July 15 2013)
search terms
1. Hemophilia OR FIX OR FVII
2. Inhibitor OR antibody
3. 1 AND 2
Appendix 3. Search terms for trials registry (July 15 2013)
Search terms
1. Hemophilia
2. Inhibitors
3. 1 AND 2
WH A T ’ S N E W
Last assessed as up-to-date: 16 April 2014.
Date Event Description
13 April 2015 Amended Contact details updated.
C O N T R I B U T I O N S O F A U T H O R S
Task Who will undertake the task?
Protocol stage: draft the protocol All authors
Review stage: select which trials to include AA, MM (AI as arbiter)
Review stage: extract data from trials AA, MM
Review stage: enter data into RevMan AA
Review stage: carry out the analysis All authors
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(Continued)
Review stage: interpret the analysis All authors
Review stage: draft the final review All authors
Update stage: update the review AA
D E C L A R A T I O N S O F I N T E R E S T
None known.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
For this version of this review, there were no differences between the protocol and the review.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Immune Tolerance; Early Termination of Clinical Trials; Factor VIII [∗administration & dosage; immunology]; Hemophilia A
[immunology; ∗therapy]; Hemophilia B [immunology; ∗therapy]; Immunosuppression [∗methods]
MeSH check words
Humans; Male
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